Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause

← catalyst calendar

NCT07118891 · readout ≤ 193 d

Sponsored by AbCellera Biologics Inc. (industry) · ABCL — their whole pipeline →.

Phase

Phase 1/2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Triple · Treatment

Enrollment

136estimated

Sites

Country

Canada

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-06-23

actual

When the study began enrolling

Primary completion

Feb 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Feb 2027

estimated

The whole study's end, after follow-up

First posted

2025-08-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-15

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Vasomotor Symptoms Associated With Menopause
Healthy Volunteers

Interventions

Biological: ABCL635
Biological: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Frequency and severity of adverse events (AE)

measured Day 0 to day 197

Number of participants with abnormalities in 12-lead safety electrocardiograms (ECG)

measured Day 0 to day 197

Number of participants with abnormalities in physical examination

measured Day 0 to day 197

Number of participants with abnormalities in laboratory parameters, including general biochemistry, hematology, endocrinology, and urinalysis

measured Day 0 to day 197

Permalink · ABCL's whole pipeline · Catalyst calendar · Every registered study · What changed